|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Abreu FB, Schwartz GN, Wells WA and
Tsongalis GJ: Personalized therapy for breast cancer. Clin Genet.
86:62–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL,
Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR,
et al: Basal-like and triple-negative breast cancers: A critical
review with an emphasis on the implications for pathologists and
oncologists. Mod Pathol. 24:157–167. 2011. View Article : Google Scholar
|
|
4
|
Győrffy B, Hatzis C, Sanft T, Hofstatter
E, Aktas B and Pusztai L: Multigene prognostic tests in breast
cancer: Past, present, future. Breast Cancer Res. 17:112015.
View Article : Google Scholar
|
|
5
|
Vasudevan S, Tong Y and Steitz JA:
Switching from repression to activation: microRNAs can up-regulate
translation. Science. 318:1931–1934. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He L, Thomson JM, Hemann MT,
Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe
SW, Hannon GJ, et al: A microRNA polycistron as a potential human
oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar
|
|
11
|
Rueff J and Rodrigues AS: Cancer drug
resistance: A brief overview from a genetic viewpoint. Methods Mol
Biol. 1395:1–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Andreasen D, Fog JU, Biggs W, Salomon J,
Dahslveen IK, Baker A and Mouritzen P: Improved microRNA
quantification in total RNA from clinical samples. Methods.
50:S6–S9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hui A, How C, Ito E and Liu FF: Micro-RNAs
as diagnostic or prognostic markers in human epithelial
malignancies. BMC Cancer. 11:5002011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Graveel CR, Calderone HM, Westerhuis JJ,
Winn ME and Sempere LF: Critical analysis of the potential for
microRNA biomarkers in breast cancer management. Breast Cancer
(Dove Med Press). 7:59–79. 2015.
|
|
17
|
Azam AT, Bahador R, Hesarikia H, Shakeri M
and Yeganeh A: Downregulation of microRNA-217 and microRNA-646 acts
as potential predictor biomarkers in progression, metastasis, and
unfavorable prognosis of human osteosarcoma. Tumour Biol. Jul
31–2015.Epub ahead of print. PubMed/NCBI
|
|
18
|
Sadeghian Y, Kamyabi-Moghaddam Z, Nodushan
SM, Khoshbakht S, Pedram B, Yahaghi E, Mokarizadeh A and Mohebbi M:
Profiles of tissue microRNAs; miR-148b and miR-25 serve as
potential prognostic biomarkers for hepatocellular carcinoma.
Tumour Biol. Jul 25–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, Li H, Wang J, Wang D, Yao A and Li
Q: Prognostic and biological significance of microRNA-127
expression in human breast cancer. Dis Markers. 2014:4019862014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gomes BC, Rueff J and Rodrigues AS:
MicroRNAs and cancer drug resistance. Methods Mol Biol.
1395:137–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sonkoly E, Wei T, Janson PC, Sääf A,
Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B,
Scheynius A, et al: MicroRNAs: Novel regulators involved in the
pathogenesis of psoriasis? PLoS One. 2:e6102007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gottardo F, Liu CG, Ferracin M, Calin GA,
Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et
al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bueno MJ, Pérez de Castro I, Gómez de
Cedrón M, Santos J, Calin GA, Cigudosa JC, Croce CM,
Fernández-Piqueras J and Malumbres M: Genetic and epigenetic
silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene
expression. Cancer Cell. 13:496–506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ru P, Steele R, Hsueh EC and Ray RB:
Anti-miR-203 upregulates SOCS3 expression in breast cancer cells
and enhances cisplatin chemosensitivity. Genes Cancer. 2:720–727.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z
and Dong JT: Epigenetic silencing of miR-203 upregulates SNAI2 and
contributes to the invasiveness of malignant breast cancer cells.
Genes Cancer. 2:782–791. 2011. View Article : Google Scholar
|
|
26
|
Chen T, Xu C, Chen J, Ding C, Xu Z, Li C
and Zhao J: MicroRNA-203 inhibits cellular proliferation and
invasion by targeting Bmi1 in non-small cell lung cancer. Oncol
Lett. 9:2639–2646. 2015.PubMed/NCBI
|
|
27
|
Yu X, Zhang X, Dhakal IB, Beggs M,
Kadlubar S and Luo D: Induction of cell proliferation and survival
genes by estradiol-repressed microRNAs in breast cancer cells. BMC
Cancer. 12:292012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang C, Zheng X, Shen C and Shi Y:
MicroRNA-203 suppresses cell proliferation and migration by
targeting BIRC5 and LASP1 in human triple-negative breast cancer
cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hailer A, Grunewald TG, Orth M, Reiss C,
Kneitz B, Spahn M and Butt E: Loss of tumor suppressor mir-203
mediates overexpression of LIM and SH3 protein 1 (LASP1) in
high-risk prostate cancer thereby increasing cell proliferation and
migration. Oncotarget. 5:4144–4153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding X, Park SI, McCauley LK and Wang CY:
Signaling between transforming growth factor β (TGF-β) and
transcription factor SNAI2 represses expression of microRNA miR-203
to promote epithelial-mesenchymal transition and tumor metastasis.
J Biol Chem. 288:10241–10253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Taipaleenmäki H, Browne G, Akech J, Zustin
J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB:
Targeting of Runx2 by miR-135 and miR-203 impairs progression of
breast cancer and metastatic bone disease. Cancer Res.
75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Madhavan D1, Zucknick M, Wallwiener M, Cuk
K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R,
et al: Circulating miRNAs as surrogate markers for circulating
tumor cells and prognostic markers in metastatic breast cancer.
Clin Cancer Res. 18:5972–5982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Imaoka H1, Toiyama Y, Okigami M, Yasuda H,
Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y and Kusunoki M:
Circulating microRNA-203 predicts metastases, early recurrence, and
poor prognosis in human gastric cancer. Gastric Cancer. Aug
2–2015.Epub ahead of print. PubMed/NCBI
|
|
34
|
Chang X, Sun Y, Han S, Zhu W, Zhang H and
Lian S: miR-203 inhibits melanoma invasive and proliferative
abilities by targeting the polycomb group gene BMI1. Biochem
Biophys Res Commun. 456:361–366. 2015. View Article : Google Scholar
|
|
35
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, et
al: Revision of the American Joint Committee on Cancer staging
system for breast cancer. J Clin Oncol. 20:3628–3636. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immuno-histochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al American Society of Clinical Oncology; College
of American Pathologists: Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American Society
of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al International Ki-67 in Breast Cancer Working Group: Assessment
of Ki67 in breast cancer: Recommendations from the International
Ki67 in Breast Cancer working group. J Natl Cancer Inst.
103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gocze K, Gombos K, Juhasz K, Kovacs K,
Kajtar B, Benczik M, Gocze P, Patczai B, Arany I and Ember I:
Unique microRNA expression profiles in cervical cancer. Anticancer
Res. 33:2561–2567. 2013.PubMed/NCBI
|
|
41
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
de Carvalho AC, Scapulatempo-Neto C, Maia
DC, Evangelista AF, Morini MA, Carvalho AL and Vettore AL: Accuracy
of microRNAs as markers for the detection of neck lymph node
metastases in patients with head and neck squamous cell carcinoma.
BMC Med. 13:1082015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu Y, Ren F, Rong M, Luo Y, Dang Y and
Chen G: Association between underexpression of microrna-203 and
clinicopathological significance in hepatocellular carcinoma
tissues. Cancer Cell Int. 15:622015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Petrović N, Mandušić V, Dimitrijević B,
Roganović J, Lukić S, Todorović L and Stanojević B: Higher miR-21
expression in invasive breast carcinomas is associated with
positive estrogen and progesterone receptor status in patients from
Serbia. Med Oncol. 31:9772014. View Article : Google Scholar
|
|
45
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009
Populations). National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2009_pops09/,
based on November 2011 SEER data submission, posted to the SEER web
site. April. 2012
|
|
46
|
Marino M, Galluzzo P and Ascenzi P:
Estrogen signaling multiple pathways to impact gene transcription.
Curr Genomics. 7:497–508. 2006. View Article : Google Scholar
|
